Our aim was to determine the factors predicting the outcome of intraprostatic injection of Botulinum Toxin-A (BTX-A) in the treatment of benign prostatic hyperplasia (BPH)-induced lower urinary tract symptoms (LUTS) and to evaluate its efficacy and safety.

Between September 2016 and May 2018, 45 Egyptian patients, with BPH-induced LUTS were included; the indication was a failure of medical treatment, unfit, or refusing surgical intervention. Measurements of prostate size by TRUS, total PSA level before and 12 weeks after injection. IPSS, uroflow, and postvoiding residual urine (PVR) were measured before injection, 2, 4, 8 and 12 weeks postinjection. 100 U BTX-A vial was diluted with 10 mL of saline then injected into the transition zone at base and midzone of the prostate by TRUS.

The mean patients’ age was 64.4 ± 6.6 years. Mean baseline IPSS 24.06 decreased to 18.75 at 2 weeks and progressively decreased to 16.37 at 12 weeks (P < 0.001), Q max of 9.08 mL/s. increased to 10.44 at 2 weeks and 11.44 at 12 weeks (P < 0.001), mean prostate volume was 67.44cc; decreased to 66.06cc (P < 0.001) at 12 weeks and mean residual urine was 82.62 mL and decreased to 57.66 mL at 12 weeks.

Intraprostatic injection of BTX-A as modality treatment of LUTS/BPH significantly improve IPSS, Q max , PVR, and decrease prostate volume. We can suspect better results with this line of treatment in patients with IPSS ≤ 22 and Q max  ≤ 10 mL/min and prostate volume ≤ 56.5cc.

The Prostate. 2019 Jun 12 [Epub ahead of print]

Ayman S Moussa, Ahmed M Ragheb, Ahmed M Abdelbary, Rabie M Ibrahim, Mahmoud S El Adawy, Ahmad Aref, Ahmed Assem, Hany Elfayoumy, Faysal Elzawy

Urology Department, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt., Urology Department, Faculty of Medicine, Fayoum University, Fayoum, Egypt., Urology Department, Faculty of Medicine, Cairo University, Cairo, Egypt.